FY 2023 Earnings Call
March 12, 2024
Jerrell Shelton | Robert Stefanovich |
CEO - Cryoport | CFO, SVP - Cryoport |
Mark Sawicki, Ph.D. | Thomas Heinzen |
Chief Scientific Officer - Cryoport | VP Investor Relations and |
and CEO - Cryoport Systems | Corporate Development - Cryoport |
Forward Looking Statements
Statements in this press release which are not purely historical, including statements regarding the Company's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to the Company's industry, business, long-term growth prospects, including the Company's belief that its clinical trials portfolio constitutes a significant long-term revenue growth opportunity, plans, strategies, acquisitions, future financial results and financial condition, such as the Company's outlook and guidance for full year 2024 revenue and the related assumptions and factors expected to drive revenue, projected growth trends in the markets in which the Company operates, the Company's plans and expectations regarding the launch of new products and services, such as the expected timing and benefits of such products and services launches, the Company's expectations about future benefits of its acquisitions, the Company's anticipation about 2024 as a year of progressive recovery in its business with stronger overall growth in the Company's services business, the Company's expectations of the continuing stabilization of MVE Biological Solutions revenue into 2024, the Company's plans to continue to build out its platform and broaden its scope with the expectation to further expand its market leading position in cell & gene therapy, and anticipated regulatory filings or approvals with respect to the products of the Company's clients. It is important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in the Company's cash flow, market acceptance risks, and technical development risks. The Company's business could be affected by other factors discussed in the Company's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward- looking statements contained in this press release speak only as of the date hereof and the Company cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, the Company disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
© 2024 CRYOPORT, INC. | 3 |
Cryoport, Inc. Organization
(NASDAQ: CYRX)
© 2024 CRYOPORT, INC. | 4 |
Cryoport - Snapshot
Performance Driven
$233.3 MM | $456.8 MM | |||||||||||
$242- $252 MM | ||||||||||||
FY 2023 Revenue | FY 2024 Revenue | Cash & Short-Term | ||||||||||
Guidance | investments | |||||||||||
C> Supply Chain Leader
14 | +33% YoY | 675 |
Commercial Cell & Gene | Commercial Cell & Gene | Active Cell & Gene |
Therapies Supported (1) | Therapies revenue | Therapy |
Clinical Trials Supported (2)
Global Platform(2)
over 50 Facilities Globally
in 17 Countries
Over 3,000+ Global Clients
1,100+ Employees
Source: Company Filings and materials
Notes: (1) Supported by Cryoport Systems as of March 12, 2024 (2) As of 12/31/2023
© 2024 CRYOPORT, INC. | 5 |
© 2024 CRYOPORT, INC. | 6 |
Growing Cell & Gene Therapy Pipeline
- 675 clinical trials (net) in aggregate
- 82 Phase III trials in the Americas, EMEA and APAC
Clinical Trials Supported by Trial Phase
as of 12/31/23
Increased by 21 trials
(net) over FY 2022
Phase III
12%
Phase I
42%
Phase II
46%
Phase I | Phase II | Phase III | ||||
Source: Company materials cross-referenced to clinical trial information publicly available
© 2024 CRYOPORT, INC. | 7 |
Clinical Trial Update
946 Industry Clinical Trials - Cryoport Supporting 675 Trials or 71%
© 2024 CRYOPORT, INC. | 8 |
CGT Clinical Trials by Phase and Region
© 2024 CRYOPORT, INC. | 9 |
Biopharma: IPO & Secondary Funding
© 2024 CRYOPORT, INC. | 10 |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Cryoport Inc. published this content on 12 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 March 2024 20:47:24 UTC.